AbbVie, a global pharmaceutical company headquartered in North Chicago, is acquiring Madison-based Nimble Therapeutics for ...

AbbVie announced a $200 million deal to acquire Nimble Therapeutics, with additional interim funding and potential development milestone payments. The acquisition includes Nimble’s lead ...

AbbVie has agreed to acquire Nimble Therapeutics for $200m in cash at closing, subject to standard adjustments, alongside potential interim funding payments. The acquisition includes Nimble's ...

AbbVie has agreed a $200 million-plus takeover deal with Roche spinout Nimble Therapeutics that will give it control of a preclinical-stage, oral drug for psoriasis. US-based Nimble was set up in ...

"Together, AbbVie and Nimble have the potential to help address the significant unmet medical need for people living with autoimmune diseases." "Nimble Therapeutics is committed to transforming ...

AbbVie is paying $200 million to snap up Nimble Therapeutics, a Roche spinout working to develop oral peptide treatments in the autoimmune space. As part of the acquisition, the North Chicago ...

(RTTNews) - AbbVie Inc. (ABBV), Friday announced an agreement to acquire Nimble Therapeutics for a cash payment of $200 million at closing, along with certain interim funding and milestone payments.

This will bring Nimble’s psoriasis and inflammatory bowel disease treatment under AbbVie’s pipeline. AbbVie will acquire Nimble Therapeutics, according to a newly announced agreement. As a result, ...

AbbVie (ABBV) and Nimble Therapeutics announced a definitive agreement under which AbbVie will acquire Nimble, including its lead asset, an investigational oral peptide IL23R inhibitor in ...